Navigation Links
Unlocking the genetics and biology of ankylosing spondylitis
Date:7/10/2011

netic regions, the first time that associations have been found in HLA-B27 negative individuals. These findings indicate considerable similarity between the way HLA-B27 positive and negative ankylosing spondylitis develop.

Professor Matt Brown from the University of Queensland, Australia, says: "Our work shows the great value of partnering genetics research with functional investigations to determine the basic biology which leads to common diseases such as ankylosing spondylitis, the causes of which have remained an enigma for so long.

"At the moment, whilst we have effective treatments to suppress the inflammation in ankylosing spondylitis, we have no treatment to substantially improve its long-term outcome, particularly the chronic pain, marked loss of movement and disability and that are common consequences of this disease. We must be cautious about the promise that these findings offer, but they are a promising step in the right direction."

Professor Alan Silman, Medical Director of Arthritis Research UK , which funded the preliminary work for the genetics research said the study was important, but added that it needed to be followed up before its significance could be measured clinically. "We're supporting further intensive work needed to investigate whether these genetic targets could offer scope for novel treatment approaches," he said.

Debbie Cook, Director of The National Ankylosing Spondylitis Society (UK) added: "We are delighted with the results of these genetic studies in ankylosing spondylitis which will help us to understand the causes of the disease better, and hopefully to develop new ideas about its treatment. Our members have been heavily involved in these studies with scientists at the University of Oxford over the past 10 years and it is good to see the progress that has been made. It has long been recognised that there is a genetic element to the condition and that it has a tendency to run in families. The
'/>"/>

Contact: Craig Brierley
c.brierley@wellcome.ac.uk
44-207-611-7329
Wellcome Trust
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Unlocking the secret(ase) of building neural circuits
2. Unlocking the secrets of a plants light sensitivity
3. Unlocking the secrets of a plant’s light sensitivity
4. Unlocking the secrets of RNA biology with WIREs
5. Unlocking the opium poppys biggest secret
6. Unlocking mysteries of the brain with PET
7. Unlocking the secret of the bladders bouncers
8. Adult stem cells carry their own baggage: Epigenetics guides stem cell fate
9. Genetics of melanoma chemoresistance
10. Population genetics reveals shared ancestries
11. MARC travel awards announced for GSA Mouse Genetics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... 2015  Based on its recent analysis of ... Credence ID, LLC with the 2015 Asia-Pacific ... Year Award. Credence ID has developed a low-cost, ... of offering enrollment and identification solutions to the ... was formed by experts from the mobile biometrics ...
(Date:7/2/2015)... , June 25, 2015 ... addition of the "Next Generation Biometrics Market by ... 2020" report to their offering. The ... Billion by 2020, at a CAGR of 17.9% between ... the leading application for the market. Safran SA ...
(Date:6/30/2015)... HATFIELD, Pa. , June 30, 2015 ... joined the company as CEO to help further develop ... a wealth of partnering experience, having spent much of ... companies including Therakine, Amgen, Baxter Bioscience, and Johnson & ... a focus on Technology and Biotech Corporate Finance. He ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... Medicine and Biology (SIUMB) have agreed to a five-year partnership ... 2013 with Volume 16. Appearing quarterly, the Journal of ... be available exclusively in electronic format on SpringerLink . ... of Ultrasound deals with significant advances in the physics, ...
... is growing scientific concern that corals could retreat from equatorial ... team of international marine researchers warned today. Working on ... episode of global warming, the period between the last two ... of a sharp decline in coral diversity near the equator. ...
... sugary foods causes chemical changes in the brain, meaning that ... drug withdrawal, according to a study published today by Dr. ... and its affiliated CRCHUM Hospital Research Centre. "By working with ... own, we discovered that the neurochemistry of the animals who ...
Cached Biology News:Springer will collaborate with the Italian Society for Ultrasound in Medicine and Biology 2Scary news for corals -- from the Ice Age 2Could ending your fatty food habit cause withdrawal symptoms and depression? 2
(Date:7/29/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ... an optimized Erk inhibitor molecule for development, thus ... a new class of potential cancer therapies. ... target for therapeutic intervention in cancer. Recently approved ... for B-Raf and Mek inhibitors. Erk inhibitors may ...
(Date:7/29/2015)... ... ... Costello served as Lead Levee Design Engineering Manager for a feasibility study ... from future storm surge flooding, such as occurred in Hurricane Ike in 2008. ... providing protection, Costello also balanced socio-economic and environmental needs and concerns. The ...
(Date:7/28/2015)... , July 29, 2015 A ... acquiring, rapidly developing and commercialising innovative medicines ...   Highly experienced management team; blue chip ...   Mereo BioPharma Group Ltd ("Mereo"), a ... $119m ( c. £76.5m), gross, from blue chip institutional ...
(Date:7/28/2015)... YORK , July 28, 2015 People ... by hearing aids achieved significant and sometimes profound improvements ... cochlear implant devices, according to a new multicenter study ... In the study, described online ahead of print in ... medical centers and private clinics in the ...
Breaking Biology Technology:Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3Preventing Storm Surge Flooding in Houston 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3
... molecules kiss, a new kind of biosensor can tell., ... by chemists at Vanderbilt University that can measure the ... antibodies, DNA and RNA., That is precisely the kind ... of research that have been opened up by the ...
... SHANGHAI, China, Sept. 20 /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. ... leading Chinese firm specializing in the manufacture,research, ... announced it has launched its newest product, ... in the Shanghai and Changchun markets. ...
... Sept. 20 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc.,(TSX:SDI) today ... Assay, a rapid diagnostic product for sepsis, in ... of the Italian,Menarini Group. Sepsis is the third ... victims each year. The treatment of severe sepsis ...
Cached Biology Technology:When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell 2When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell 3China-Biotics, Inc. Launches Shining Probiotics Protein Powder 2Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany 2